Halozyme Therapeutics (HALO)
(Real Time Quote from BATS)
$59.09 USD
-0.15 (-0.25%)
Updated Sep 23, 2024 11:22 AM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Brokerage Reports
Halozyme Therapeutics, Inc. [HALO]
Reports for Purchase
Showing records 1 - 20 ( 203 total )
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Top-, Bottom-Line Beat; Guidance Affirmed; 2Q24 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DARZALEX FASPRO U.S. Label Broadened in Multiple Myeloma; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Subcutaneous Efgartigimod Approved in China; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Second ENHANZE Approval in a Week; OCREVUS SC EU Mandate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Another ENHANZE Win; VYVGART Hytrulo Gets CIDP Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Patent Boosts EU Darzalex SC Royalty; Guidance Improved; Raising PT to $65
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Another Enhanze Win Via Subcutaneous RYBREVANT Data at ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Accelerated U.S. Approval Decision Date for Opdivo SC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Financial Results; Long-Term Guidance Reaffirmed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Opdivo SC Coming Soon; Wave 3 Execution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
European Agency Recommends OCREVUS SC For Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M